AtriCure (NASDAQ:ATRC) will be issuing its quarterly earnings data after the market closes on Monday, February 26th. Analysts expect the company to announce earnings of ($0.21) per share for the quarter.
Shares of AtriCure (ATRC) opened at $18.00 on Friday. The company has a market cap of $593.64, a PE ratio of -17.65 and a beta of 0.39. AtriCure has a 1 year low of $14.88 and a 1 year high of $25.18. The company has a current ratio of 2.28, a quick ratio of 1.65 and a debt-to-equity ratio of 0.20.
ATRC has been the subject of several analyst reports. Piper Jaffray Companies reissued a “buy” rating and set a $24.00 price target on shares of AtriCure in a research report on Sunday, December 10th. TheStreet lowered shares of AtriCure from a “c-” rating to a “d+” rating in a research report on Wednesday, November 29th. ValuEngine lowered shares of AtriCure from a “hold” rating to a “sell” rating in a research report on Wednesday, November 15th. Canaccord Genuity decreased their price target on shares of AtriCure from $28.00 to $24.00 and set a “buy” rating for the company in a research report on Thursday, November 2nd. Finally, Needham & Company LLC decreased their price target on shares of AtriCure from $26.00 to $25.00 and set a “buy” rating for the company in a research report on Thursday, November 2nd. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and six have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $24.33.
AtriCure Company Profile
AtriCure, Inc is an atrial fibrillation (Afib) solutions company. The Company develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. It has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures.
Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.